All In Biotech

Drug Trial Radar · NCT02815670

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.

Last checked: Nov 20, 2026Latest source record: Apr 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1

Actual

Start

Sep 7, 2016

Primary completion

Oct 19, 2019

Study completion Oct 19, 2019

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial objective is to demonstrate the safety of idarucizumab, as assessed by the occurence of patients with drug related adverse events (including immune reactions) and all-cause mortality in paediatric venous thromboembolism patients treated with dabigatran in ongoing clinical trials who require emergency surgery/urgent procedures or patients who have life-threatening or uncontrolled bleeding which requires urgent intervention, when rapid reversal of the anticoagulant effect of dabigatran is needed.

Conditions

  • Hemorrhage

Interventions

  • IdarucizumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Drug-related Adverse Events (AEs)Time frame: From vial 1 of Idarucizumab until prematurely discontinued of the trial, up to 25 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan

    Kazan', Russia

  • Regional Clin.Hosp.1,Congen.heart defects&child.Cardiol.dept

    Tyumen, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.